New Ethiqa XR from Fidelis Pharmaceuticals is the first and only pharmaceutical grade extended-release buprenorphine that’s FDA-affirmed to control post-procedural pain for laboratory mice and rats up to 72 hours after just one injection. See efficacy and safety.
Ethiqa XR is now available through MWI Animal Health and Covetrus
An Ethical Imperative
Effective pain management for laboratory animals is an essential need in today’s research. Learn more about industry association guidelines.
Want to learn more? Register for a webinar or to stay up-to-date on product availability.
Manufactured in Harleysville, Pa.
Important Safety Information for Rats and Mice, Not for use in humans
Only administer Ethiqa XR™ by subcutaneous injection. Ethiqa XR™ is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR™. Use caution with concomitant administration of Ethiqa XR™ with drugs that cause respiratory depression. Ethiqa XR™ should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.
For more information, consult the prescribing information including the boxed warning.